For millions of patients with type 2 diabetes, managing blood pressure is a delicate balancing act. Doctors routinely prescribe a cocktail of renin-angiotensin inhibitors (RASi) and SGLT2 inhibitors—a combination widely considered the gold standard for shielding the kidneys from long-term damage. But a new study suggests that adding a common class of blood pressure medication to this regimen might inadvertently undermine those protective effects.

Researchers presenting at the European Renal Association congress in Glasgow found that patients taking dihydropyridine calcium-channel blockers (DCCBs) alongside these standard therapies faced a higher risk of major adverse kidney events. The findings, based on a retrospective analysis of more than 31,000 patients, suggest that the standard "second-line" treatment for hypertension may not be as benign as once thought for those already on modern kidney-protective drugs.

The Data Behind the Risk

Led by Dr. Timna Agur of Tel-Aviv University, the research team analyzed data from Clalit Health Services between 2016 and 2021. The cohort included 31,041 adults with type 2 diabetes, all of whom were already receiving the recommended RASi and SGLT2i therapy.

During a median follow-up period of 1,260 days, the researchers tracked two primary outcomes: major adverse kidney events and mortality. The results were stark: patients prescribed a DCCB were 29 percent more likely to experience a major adverse kidney event compared to those who were not. This increased risk remained statistically significant even after the researchers adjusted for the competing risk of death.

Why This Matters for Clinical Practice

DCCBs, such as amlodipine, are staples in cardiology. They are frequently the go-to choice when a patient’s blood pressure remains uncontrolled despite initial treatment. However, the mechanism by which they lower pressure—by relaxing the smooth muscles of blood vessels—may have unintended consequences for the delicate filtration system of the kidneys when combined with other potent medications.

"DCCBs are widely used as second-line blood pressure treatments in patients with diabetic kidney disease," Agur said in a statement. The study forces a re-evaluation of that standard practice. If these drugs are blunting the benefits of SGLT2 inhibitors, clinicians may need to look toward alternative antihypertensive agents that do not carry the same risk profile for patients with established diabetic kidney disease.

What Experts Say

While the study provides a compelling signal, nephrologists caution that it is observational. Retrospective data can identify associations, but it cannot definitively prove that the DCCBs themselves caused the kidney decline. Factors such as the severity of the underlying disease or the specific reasons a physician chose a DCCB over another agent could influence the results.

Nevertheless, the sheer size of the cohort—over 31,000 patients—gives the findings significant weight. The medical community is now looking for prospective trials to confirm whether switching to non-DCCB alternatives for blood pressure control can preserve kidney function more effectively in this specific population.

Key Takeaways

  • A retrospective study of 31,041 patients found that DCCB use was associated with a 29 percent higher risk of major adverse kidney events in T2D patients already on RASi and SGLT2i therapy.
  • The findings challenge the common practice of using DCCBs as a standard second-line treatment for hypertension in patients with diabetic kidney disease.
  • Researchers suggest that clinicians should reconsider whether DCCBs are the optimal choice for patients already receiving modern, kidney-protective drug regimens.

Next Steps for Patients and Providers

The next major hurdle for researchers is to determine if these findings hold up in randomized controlled trials, which are the gold standard for establishing causality. For now, the study serves as a critical prompt for physicians to review the medication lists of their T2D patients. As clinical guidelines evolve, the focus will likely shift toward identifying which specific antihypertensive agents best complement, rather than compete with, the protective effects of SGLT2 inhibitors. Patients should not discontinue any prescribed medication without consulting their physician, as the immediate risk of uncontrolled hypertension remains a primary concern.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.